Amy Gutmann: A look back at her 18-year presidency thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.
Penn researchers weigh in on the regulatory and scientific efforts to track COVID-19 vaccines. Between December 2020 and February 2021, three drugmakers received Emergency Use Authorizations to distribute COVID-19 vaccines. The next step is a biologics license application the technical name for full approval a process Pfizer and Moderna have already begun. Experts from Penn are keeping a close eye on these regulatory steps, as well as the reporting mechanisms involved in assessing vaccine safety. The outlook thus far seems promising. (Image: Daniel Schlud)
The mRNA vaccines for COVID-19, made by Pfizer/BioNTech and Moderna, are among the most powerful vaccines the world has ever seen. According to clinical trial data, they are more than 94% effective at preventing symptomatic disease, with real-world data bearing out that success. The other vaccine currently available in the U.S., produced by Janssen, uses a viral
Penn Medicine s frontline health workers and researchers have begun receiving COVID-19 vaccinations including the Penn scientists whose findings on mRNA technology laid the groundwork for the vaccines to be developed.